Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 196 AL 210

A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease

Alshehri GH, Al-Kuraishy HM, Al-Gareeb AI, Fawzy MN, Waheed HJ, Papadakis M, Alexiou A, El-Saber Batiha G.

Eur J Pharmacol. 2025 Sep 15;1003:177979. doi: 10.1016/j.ejphar.2025.177979. Epub 2025 Jul 22.

Phytocompounds as modulators of HSF1 in neurodegenerative disease: Special emphasis on Alzheimer's disease

Nelson VK, Begum MY, Dera AA, Ali SP, Suryadevara PR.

Eur J Pharmacol. 2025 Oct 15;1005:178034. doi: 10.1016/j.ejphar.2025.178034. Epub 2025 Aug 5.

PANoptosis: Potential Therapeutic Prospects in Alzheimer's Disease

Guo Z, Wan Y.

Eur J Neurosci. 2025 Aug;62(4):e70231. doi: 10.1111/ejn.70231.

The emerging role of disulfidptosis in Alzheimer's disease

Zhou Q, Zheng N, Chen Z, Xie L, Yang X, Sun Q, Lin J, Li B, Li L.

Eur J Pharmacol. 2025 Oct 15;1005:178085. doi: 10.1016/j.ejphar.2025.178085. Epub 2025 Aug 21.

Cannabidiol and Alzheimer Disease: A Comprehensive Review and In Silico Insights Into Molecular Interactions

Mello-Hortega JV, de Oliveira CS, de Araujo VS, Furtado-Alle L, Tureck LV, Souza RLR.

Eur J Neurosci. 2025 Aug;62(4):e70229. doi: 10.1111/ejn.70229.

Insights into CYP450 polymorphisms and their impact on drug metabolism in Alzheimer's disease therapy

Zheng J, Liu G, Wang Q, Liang Y.

Drug Metab Rev. 2025 Nov;57(4):523-534. doi: 10.1080/03602532.2025.2552786. Epub 2025 Sep 3.

[Aβ Receptor PirB and its regulation by LOTUS]

Kawaguchi Y, Takei K.

Nihon Yakurigaku Zasshi. 2025;160(5):318-323. doi: 10.1254/fpj.25018.

Hydrogen sulfide in the brain as a silent neuroprotector in Alzheimer's disease

Layal H, Rajbongshi J, Kumar R, Pandey S, Mishra R, Yadav PK.

Neuroscience. 2025 Oct 15;585:181-197. doi: 10.1016/j.neuroscience.2025.08.057. Epub 2025 Sep 2.

[Anti-amyloid antibodies for the treatment of early-stage Alzheimer's disease]

Frederiksen KS, Gramkow MH, Hasselbalch SG, Law I, Waldemar G.

Ugeskr Laeger. 2025 Aug 25;187(35):V03250217. doi: 10.61409/V03250217.

Acetylcholinesterase as a Multifunctional Target in Amyloid-Driven Neurodegeneration: From Dual-Site Inhibitors to Anti-Agregation Strategies

Grabowska W, Bijak M, Szelenberger R, Gorniak L, Podogrocki M, Harmata P, Cichon N.

Int J Mol Sci. 2025 Sep 7;26(17):8726. doi: 10.3390/ijms26178726.

Medicinal chemistry-based novel herapeutics for Tauopathies in Alzheimer's disease

Chinnathambi S, Malik S, Chandrashekar M, Kumurappan M.

Adv Protein Chem Struct Biol. 2025;147:151-175. doi: 10.1016/bs.apcsb.2024.09.001. Epub 2024 Sep 20.

Role and relation of cell death in Alzheimer's disease

Hoang DA, Le DA, Do TMH, Than VT.

Prog Mol Biol Transl Sci. 2025;217:263-303. doi: 10.1016/bs.pmbts.2025.06.024. Epub 2025 Jul 1.

Targeting Metabolic Dysregulation in Alzheimer's Disease: A Potential Therapeutic Strategy

Barnwal N, Dubey S, Tiwari P.

Curr Drug Metab. 2025;26(7):455-471. doi: 10.2174/0113892002408089250912080734.

Perspectives on Alzheimer's Disease Treatment Based on Counteracting Oxidative Stress

Bilski R, Dąbkowski S, Kozieł I, Kozicki M, Małachowska A, Przygocki M, Tyska O.

Biomolecules. 2025 Sep 19;15(9):1345. doi: 10.3390/biom15091345.

[Disease-modifying therapy with lecanemab for early Alzheimer's dementia]

Hansen N, Wiltfang J.

Fortschr Neurol Psychiatr. 2025 Nov;93(11):453-460. doi: 10.1055/a-2681-4558. Epub 2025 Oct 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias